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 To determine the efficacy and tolerability of a 
standardized protocol of repeated blocks of 
pericranial nerves in the management of 
chronic migraine
 Many patients with chronic migraine fail typical 
modalities
 Our clinical experience with pericranial blocks 
in the management of status migrainosus
detected a subset of patients describing long-
lasting results from their injections
 Typically 3 months
 Pericranial nerve blocks have been used for 
decades to treat a variety of headache 
disorders
 Occipital nerve blocks have been shown to be 
effective in acute migraine and “chronic daily 
headache”, as well as cluster and cervicogenic
headaches
 Prior work has involved heterogeneous 
populations and unstandardized protocols
 Single-center, prospective, open-label study
 Subjects
 Adult population, ages 18-65
 Males or non-pregnant females
 Diagnosis of chronic migraine (ICHD-IIR criteria)
 Failure of 3 adequate trials of preventive medications
 Absence of opioid or butalbital use
 Absence of prior reaction to local anesthetic agents
 Protocol
 Administration of pericranial injections
 12-week intervals
 4 sets of injections over 48 weeks
 Fixed-dose (0.1 cc of 0.25% bupivacaine)
 Fixed-site (17 pericranial nerve injections each side)
 10 injections: Greater and lesser occipital
 5 injections: Auriculotemporal and zygomaticotemporal
 2 injections: Supraorbital and supratrochlear

 Primary endpoint
 Mean change from baseline in the monthly frequency 
of headache days at week 48
 Response defined as >50% reduction
 Secondary endpoints
 Mean change in monthly severe headache days
 Mean change in monthly acute medication days
 Mean change in HIT-6 disability scores
 218 subjects enrolled and treated
Baseline Characteristics (n=218)
Female (%) 87.1
Age (years) 40.4
History of migraine (years) 18.5
Headache days per 4 weeks 21.4
Severe headache days per 4 weeks 15.5
Acute treatment days per 4 weeks 18.3
HIT-6 score 66.2
 116 subjects (53.2%) met the primary endpoint 
with >50% reduction from baseline in monthly 
frequency of headache days at 48 weeks
 77 subjects (35.3%) with response < 4 weeks
 25 subjects (11.5%) with no response or lost to 
follow-up
 Responder subgroup analysis (n=116)
 Mean monthly headache days from 22.8 to 9.0
 Mean monthly severe headache days from 15.9 to 6.1
 Mean monthly acute treatment days from 18.1 to 7.9 
 Mean HIT-6 score from 66.7 to 59.2
 No clinical or demographic differences versus the 
nonresponder subgroup
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 Adverse events (n=585 sets of injections)
 Local discomfort: 581
 Immediate: 581 (99.3%)
 Prolonged (>24 hours): 77 (13.2%)
 Local numbness/paresthesias
 Immediate: 502 (86.4%)
 Prolonged (>24 hours): 5 (1%)
 Nausea: 44 (7.5%)
 Dizziness: 18 (3%)
 Syncope: 1 (<.05%)
 Worsening headache frequency: 3 (.05%)
 A standardized program of pericranial nerve 
blocks performed at 12-week intervals was 
effective and well tolerated over the course of 
48 weeks in adults with chronic migraine
